COVID-19 (Coronavirus) Update: Testing and Information | Vaccine Updates | Visitor Guidelines

A Phase I Study of GNX102 in Patients with Advanced Solid Tumors

Protocol No
GLYCONEX-GNX-001
Principal Investigator
Ben George
Phase
I
Summary
This study is being performed to Test several doses of GNX102, and Determine the initial safety of GNX102, See what effects (good and bad) it has on you and your cancer. Find the highest dose of GNX102 that can be given without causing serious side effects when treatment is given intravenously (IV or in a vein) once every 3 weeks. Find the dose of GNX102 that should be used in future studies. Evaluate how long the study medication stays in the body.
Description
This new medicine, GNX102, is an antibody that binds to a certain target on the surface of the cancer cells and may kill the cancer cells.

The purposes of this study are to determine the right dose of GNX102 that can be tolerated by people with cancer, and, if it can shrink the tumors.
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL